1931 - 1940 of 7785 Results
Title
Year
- White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia2022RESTRICTEDTitle: White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementiaJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 111Issue #:Start Page: 54End Page: 63Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2021.11.007Best OA location URL: http://escholarship.mcgill.ca/downloads/ns064b900Citation Count: 33
- A novel risk calculator predicting surgical site infection after spinal surgery in patients with cerebral palsy2022RESTRICTEDTitle: A novel risk calculator predicting surgical site infection after spinal surgery in patients with cerebral palsyJournal Name: Developmental Medicine & Child NeurologyPublisher: WileyVol: 64Issue #: 8Start Page: 1034End Page: 1043Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1111/dmcn.15193Citation Count: 1
-
RESTRICTEDTitle: The Disease Modification Conundrum in Parkinson’s Disease: Failures and HopesJournal Name: Frontiers in Aging NeurosciencePublisher: Frontiers Media SAVol: 14Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnagi.2022.810860Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnagi.2022.810860/pdfCitation Count: 22
- NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation2022RESTRICTEDTitle: NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome ActivationJournal Name: International Journal of InflammationPublisher: Hindawi LimitedVol: 2022Issue #:Start Page: 1End Page: 12Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1155/2022/2337363Best OA location URL: https://downloads.hindawi.com/journals/iji/2022/2337363.pdfCitation Count: 4
-
RESTRICTEDTitle: A Randomized, Double‐Blind, Controlled Phase II Study of Foliglurax in Parkinson's DiseaseJournal Name: Movement DisordersPublisher: WileyVol: 37Issue #: 5Start Page: 1088End Page: 1093Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.28970Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mds.28970Citation Count: 24
-
RESTRICTEDTitle: Physician‐Assisted Dying: Access and Utilization in Patients with Movement DisordersJournal Name: Movement DisordersPublisher: WileyVol: 37Issue #: 4Start Page: 694End Page: 698Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.28964Citation Count: 2
- Validation of the Arabic Version of the Movement Disorder Society‐Unified Parkinson's Disease Rating Scale2022RESTRICTEDTitle: Validation of the Arabic Version of the Movement Disorder Society‐Unified Parkinson's Disease Rating ScaleJournal Name: Movement DisordersPublisher: WileyVol: 37Issue #: 4Start Page: 826End Page: 841Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.28905Citation Count: 4
- CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers2022RESTRICTEDTitle: CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative BiomarkersJournal Name: Frontiers in NeurologyPublisher: Frontiers Media SAVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.3389/fneur.2022.834580Best OA location URL: https://www.frontiersin.org/articles/10.3389/fneur.2022.834580/pdfCitation Count: 20
-
RESTRICTEDTitle: Etiology, pathological characteristics, and clinical management of black pleural effusionJournal Name: MedicinePublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 101Issue #: 8Start Page: e28130End Page: e28130Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1097/md.0000000000028130Best OA location URL: https://doi.org/10.1097/md.0000000000028130Citation Count: 6
-
RESTRICTEDTitle: Nanobodies as allosteric modulators of Parkinson’s disease–associated LRRK2Journal Name: Proceedings of the National Academy of SciencesPublisher: Proceedings of the National Academy of SciencesVol: 119Issue #: 9Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1073/pnas.2112712119Best OA location URL: https://doi.org/10.1073/pnas.2112712119Citation Count: 22